Genizon Biosciences Announces a License and Collaboration Agreement with Pfizer in Three Major Diseases
Collaboration using "Quebec Founder Population" in genome-wide association studies to be used to develop diagnostics
Genizon BioSciences announced a license and collaboration agreement with Pfizer Inc. for diagnostic rights to Genizon's discovery programs in Alzheimer's disease, attention deficit hyperactivity disorder and endometriosis. Genizon retains therapeutic rights.
Under the terms of the agreement, Pfizer will pay Genizon upfront license fees and funding for research on genetic variations associated with diseases. Pfizer will also purchase an equity stake in Genizon subject to certain closing conditions. Financial terms were not disclosed.
The collaboration involves discovery of diagnostic markers from three ongoing genome-wide association studies of the Quebec Founder Population using Genizon's proprietary technology platform. The collaboration will expand these discoveries by including results with those from genome-wide association studies from general populations.
Other news from the department business & finance
